Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 7.55 USD -9.8% Market Closed
Market Cap: 46.1m USD

Intrinsic Value

ALGS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ALGS stock under the Base Case scenario is 4.08 USD. Compared to the current market price of 7.55 USD, Aligos Therapeutics Inc is Overvalued by 46%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALGS Intrinsic Value
4.08 USD
Overvaluation 46%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Aligos Therapeutics Inc

Valuation History Unavailable

Historical valuation for ALGS cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare ALGS to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ALGS?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Aligos Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aligos Therapeutics Inc

Current Assets 143.2m
Cash & Short-Term Investments 137.9m
Other Current Assets 5.3m
Non-Current Assets 7.5m
PP&E 6.9m
Other Non-Current Assets 632k
Efficiency

Free Cash Flow Analysis
Aligos Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Aligos Therapeutics Inc

Revenue
3.3m USD
Operating Expenses
-89.6m USD
Operating Income
-86.4m USD
Other Expenses
33.1m USD
Net Income
-53.3m USD
Fundamental Scores

ALGS Profitability Score
Profitability Due Diligence

Aligos Therapeutics Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
Negative Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROIC
12/100
Profitability
Score

Aligos Therapeutics Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

ALGS Solvency Score
Solvency Due Diligence

Aligos Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
67/100
Solvency
Score

Aligos Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALGS Price Targets Summary
Aligos Therapeutics Inc

There are no price targets for ALGS.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Aligos Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALGS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ALGS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ALGS stock?

The intrinsic value of one ALGS stock under the Base Case scenario is 4.08 USD.

Is ALGS stock undervalued or overvalued?

Compared to the current market price of 7.55 USD, Aligos Therapeutics Inc is Overvalued by 46%.

Back to Top